Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
F. A. Lempp, T. Volz, E. Cameroni, F. Benigni, J. Zhou, L. E. Rosen, J. Noack, F. Zatta, H. Kaiser, S. Bianchi, G. Lombardo, S. Jaconi, H. Imam, L. B. Soriaga, N. Passini, , M. A. Schmid
This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.
bioRxiv · Sep 9, 2022Microbiology
Y.-J. Park, D. Pinto, A. C. Walls, Z. Liu, A. De Marco, F. Benigni, F. Zatta, C. Silacci-Fregni, J. Bassi, K. R. Sprouse, A. Addetia, J. E. Bowen, C. Stewart, M. Giurdanella, C. Saliba, , Piccoli
This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.
bioRxiv · May 8, 2022Immunology
E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P
This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.
bioRxiv · Dec 12, 2021Immunology
Y.-J. Park, A. De Marco, T. N. Starr, Z. Liu, D. Pinto, A. C. Walls, F. Zatta, S. K. Zepeda, J. E. Bowen, K. S. Sprouse, A. Joshi, M. Giurdanella, B. Guarino, J. Noack, R. Abdelnabi, , D. Veesler
This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.
bioRxiv · Oct 13, 2021Immunology
M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom
This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.
bioRxiv · Apr 7, 2021 · PreprintImmunology
T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, , Veesler
This study identifies antibodies against SARS-CoV-2 that balance neutralization potency and breadth, with some showing high resistance to viral escape.
bioRxiv · Apr 6, 2021 · PreprintMicrobiology
M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler
The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.
bioRxiv · Jan 14, 2021Immunology
E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols
The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.
bioRxiv · Nov 4, 2020Microbiology
D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti
This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.
bioRxiv · Apr 7, 2020Immunology